Are Wall Street Analysts Bullish on Zimmer Biomet Stock?

ZBH, a company headquartered in Indiana, specializes in manufacturing and selling medical equipment like orthopedic, dental, and spinal reconstructive implants. Despite underperforming the broader market in the past year, the stock has shown strong domestic momentum. This success has been driven by gains in the U.S. hip market and strong sales of robotics products.

However, international hurdles, such as challenges in China's procurement and price erosion in non-core trauma and restorative therapies, have impacted overall performance. In the second quarter, ZBH exceeded expectations with adjusted earnings per share of $2.07, surpassing estimates of $2.01. Analysts anticipate continued growth, with projected full-year adjusted EPS of $8.53, a 4% increase from the current price.

Currently, 29 analysts have rated ZBH with a "Hold" consensus, with some recommending "Strong Buy" and others suggesting "Strong Sell." The mean price target stands at $104.67, indicating a potential 5.1% upside from the current stock price.